Changeflow GovPing Pharma & Drug Safety Retron Gene Editing Patent for Human Cell Genome
Routine Notice Added Final

Retron Gene Editing Patent for Human Cell Genome

Favicon for changeflow.com USPTO Patent Applications - Biotech (C12N)
Published
Detected
Email

Summary

USPTO published patent application US20260091137A1 for Retron directed gene editing technology applicable to human cell genome editing. The application, filed September 15, 2023, by inventors Brian Busser and colleagues, covers compounds, polypeptides, compositions, and nucleic acid molecules for genome editing. Key CPC classifications include gene editing enzymes and genetic constructs.

Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

USPTO published patent application US20260091137A1 for a Retron directed gene editing system applicable to human cells. The application claims compounds, polypeptides, compositions, and nucleic acid molecules useful for genome editing. Inventors include Brian Busser, Johann Neil Reshan Cooke, Robin L. Armstrong, Gregory Mazo, Glenn Christopher Tan, and Madyson Scherr. Filing date was September 15, 2023, with application number 19111662.

This is a patent application publication providing intellectual property notice rather than imposing compliance obligations. Companies developing gene editing technologies, particularly retron-based systems, should review the claims to assess potential licensing needs or freedom-to-operate implications. Researchers and biotech firms in genetic medicine, therapeutic development, and synthetic biology should monitor this application through the prosecution period.

Archived snapshot

Apr 2, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

RETRON DIRECTED GENE EDITING

Application US20260091137A1 Kind: A1 Apr 02, 2026

Inventors

Brian Busser, Johann Neil Reshan Cooke, Robin L. Armstrong, Gregory Mazo, Glenn Christopher Tan, Madyson Scherr

Abstract

Compounds, polypeptides, compositions, and nucleic acid molecules are provided herein that can be used, for example, to edit the genome of a cell, such as a human cell.

CPC Classifications

A61K 48/0058 C12N 9/1276 C12N 9/226 C12N 15/11 C12N 15/85 C12N 2310/20 C12N 2800/107 C12N 2800/22

Filing Date

2023-09-15

Application No.

19111662

View original document →

Get daily alerts for USPTO Patent Applications - Biotech (C12N)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 2nd, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
US20260091137A1

Who this affects

Applies to
Pharmaceutical companies Healthcare providers Drug manufacturers
Industry sector
3254 Pharmaceutical Manufacturing 6211 Healthcare Providers
Activity scope
Biotechnology R&D Genetic Engineering
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Healthcare Pharmaceuticals

Get alerts for this source

We'll email you when USPTO Patent Applications - Biotech (C12N) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!